Autoimmune therapy - Cartesian Therapeutics
Alternative Names: ImmTORTM PBCLatest Information Update: 05 Dec 2023
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Hepatoprotectants
- Mechanism of Action Dendritic cell stimulants; Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Primary biliary cirrhosis
Most Recent Events
- 01 Jun 2021 Preclinical pharmacodynamic data released by Selecta Biosciences
- 01 Jun 2021 Selecta Biosciences plans clinical trial in primary biliary cholangitis
- 16 Mar 2021 Autoimmune therapy - Selecta Biosciences is available for licensing as of 16 Mar 2021. https://selectabio.com/portfolio/autoimmune/